Everads anti-VEGF gene therapy

Everads anti-VEGF gene therapy is an investigational therapeutic candidate developed by Everads Therapy for the treatment of neovascular age-related macular degeneration (nAMD). The program utilizes the company's proprietary suprachoroidal delivery technology to administer a gene therapy vector—typically an adeno-associated virus (AAV)—that encodes an anti-vascular endothelial growth factor (anti-VEGF) protein. By delivering the therapy into the suprachoroidal space, Everads aims to achieve more effective and durable distribution of the transgene across the posterior segment of the eye compared to traditional intravitreal injections. The primary goal is to provide long-term suppression of VEGF, thereby reducing the frequency of treatments and improving clinical outcomes for patients with 'wet' AMD.

Other names

anti-VEGF-Everads Therapy-VEGF-Gene Therapy-Neovascular Age-related Macular Degeneration (nAMD)Everads nAMD gene therapyEverads suprachoroidal anti-VEGF gene therapy